sorafenib has been researched along with Thyrotoxicosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barbaro, D | 1 |
| Daimon, M; Kaino, W; Kameda, W; Karasawa, S; Kato, T; Oizumi, T; Susa, S; Takase, K; Tomita, Y; Wada, K | 1 |
2 other study(ies) available for sorafenib and Thyrotoxicosis
| Article | Year |
|---|---|
Sorafenib and thyrotoxicosis.
Topics: Benzenesulfonates; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prednisone; Pyridines; Sorafenib; Thyrotoxicosis | 2010 |
Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thyroid Diseases; Thyroid Gland; Thyrotoxicosis | 2012 |